Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2025 Dec 1;39(23):e71245. doi: 10.1096/fj.202503386R

Vascular Bed‐Specific Endothelial Dysfunction and Age‐Dependent Circadian Hypertension in Mice Lacking the Resolvin D2 Receptor GPR18

Sofie de Moudt 1, Barbara Sitek 2, Anna Bar 2, Marc‐Damien Lourenco‐Rodrigues 1, Jérémy Lagrange 1,3, Frances T Yen 1, Stefan Chłopicki 2,4, Nathalie Mercier 1, Magnus Bäck 1,5,6,7,✉
PMCID: PMC12668024  PMID: 41324396

ABSTRACT

G protein‐coupled receptor (GPR) 18 is the receptor for the specialized pro‐resolving lipid mediator (SPM) RvD2, which has proven efficacy in preventing atherosclerosis in mice. The aim of the present study was to establish direct vascular effects of GPR18 signaling. GPR18 knockout (KO) and wildtype (WT) mice underwent magnetic resonance imaging (MRI) for in vivo determination of endothelial function, and continuous 24 h telemetry for in vivo blood pressure monitoring. Isolated vessels derived from GPR18 KO and wildtype mice were used for determinations of ex vivo vascular reactivity and immunofluorescent quantifications. GPR18 KO mice exhibited endothelial dysfunction in the femoral arterial segment measured by MRI in vivo and in isolated arteries ex vivo as impaired ACh‐induced vasodilatation, whereas the sensitivity to exogenous NO was unchanged. Endothelial function was not significantly different in the thoracic aortic segment between GPR18 KO and WT mice, demonstrating vascular bed‐specific endothelial dysfunction as a result of GPR18 deletion. A significantly reduced eNOS expression and a larger indomethacin‐sensitive component in ACh‐induced relaxations observed in femoral arteries derived from GPR18 KO compared with WT mice suggest that the dysfunctional eNOS‐mediated femoral endothelial function may be partly compensated by increased relaxant prostanoid modulation. Finally, conscious mean arterial blood pressure recorded by telemetry was significantly higher daytime compared with wildtype mice at 24 h telemetry measures, whereas young mice did not exhibit any significant differences in day‐ and night‐time blood pressure. These observations linking GPR18 to vascular bed‐specific endothelial dysfunction and age‐dependent hypertension point to beneficial pro‐resolving cardiovascular effects through GPR18 during aging.

Keywords: endothelial dysfunction, GPR18, hypertension, resolution of inflammation, resolvin D2


Resolvin D2 is a specialized pro‐resolving mediator transducing atheroprotective effects on myeloid cells through the GPR18 receptor. This study provides the first evidence that GPR18: Is critical for maintaining endothelial function in muscular, but not elastic, arteries. Directly protects against the development of age‐associated, circadian hypertension. GPR18 emerges as a therapeutic target for maintaining endothelial function and preventing a hypertensive phenotype with aging.

graphic file with name FSB2-39-e71245-g001.jpg

1. Introduction

An emerging risk factor for cardiovascular disease (CVD) is the presence of unresolved chronic vascular inflammation [1]. A failure to resolve inflammation results from an imbalance between pro‐inflammatory pro‐resolving mediators. The latter mediator class comprises bioactive lipids referred to as specialized pro‐resolving mediators (SPMs) [2], which transduce active resolution of inflammation through interaction with G protein‐coupled receptors (GPR) [3] leading to healing of the inflammation site and re‐establishment of tissue homeostasis [4]. Therefore, pro‐resolution treatment for acute or chronic CVD could potentially reduce CVD risk without interfering with appropriate immune responses that are crucial for protection against harmful stimuli.

Within the SPMs class, resolvin (Rv) D2 is derived from the omega‐3 polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) [5] and activates the G‐protein‐coupled receptor GPR18 [3]. While evidence has accumulated for a beneficial role for RvD2 in the context of atherosclerosis [6, 7] and hypertension [8, 9], less is known about GPR18 regulation of the cardiovascular phenotype.

Although a multitude of effects have been described for the GPR18/RvD2 axis in the resolution of cardiovascular inflammation through effects on myeloid cells [3, 10, 11], recent evidence suggests that RvD2 in addition exerts direct effects on vascular structural cells [9]. GPR18 has previously been shown to be expressed in endothelial cells [8] and RvD2 induces the production of vasorelaxant substances, including nitric oxide (NO) and prostacyclin [12], indicating an SPM‐regulated vasodilation through NO synthase (NOS)‐ and cyclooxygenase (COX)‐dependent mechanisms.

The aim of the present study was to establish direct effects of GPR18 in vasoactive signaling to decipher the role and pathophysiological role of GPR18 across multiple vascular beds.

Three major observations emerged from the present study. First, endothelial dysfunction was detected both in vivo and in vitro in the femoral circulation of mice lacking GPR18, which contrasted with findings in the thoracic aorta, suggesting vascular bed‐specific vasorelaxant modulations through GPR18. Second, the dysfunctional NO‐mediated endothelial relaxations were in part compensated for by an activation of the COX pathway in the femoral arterial segments from GPR18‐deficient mice. Third, old mice lacking GPR18 had a significantly elevated pressure during daytime. Taken together, these results point to a vascular bed‐specific role for GPR18 in maintaining NO‐dependent vasorelaxation, compensatory relaxant prostanoid pathways, and linked GPR18 to an age‐dependent circadian hypertensive phenotype.

2. Material and Methods

The breeding and experimental protocols in GPR18 KO (MGI:107859; NCBI ID: 110168; C57BL/6J‐Gpr18em1cyagen) mice and WT littermates were approved by the local ethics committee and the Ministry of National Education, Higher Education, and Research and Innovation in France (APAFIS#22187‐2 019 093 011 424 973 v5). MRI experiments were approved by the Local Ethics Committee of Jagiellonian University (Krakow, Poland, identification code: 339/2022). All laboratory animal housing and experiments were conducted in accordance with the guidelines of the European Community (Directive 2010/63/EU) and were in accordance with the Guide for the Care and Use of Laboratory Animals of the National Academy of Sciences (NIH publication No. 85–23, revised 1996). Further details are provided as extended methods in Data S1.

3. Results and Discussion

Magnetic Resonance Imaging (MRI) revealed a significant impairment of endothelium‐dependent relaxation in the femoral artery of GPR18 knockout (KO) mice compared with wild type (WT) controls (Figure 1A), providing the first direct evidence that GPR18 is required to preserve endothelial function. In contrast, aortic acetylcholine (Ach)‐induced vasodilation was unaffected by GPR deletion (Figure 1B), supporting the concept that GPR18 exerts vascular bed–specific effects, with muscular arteries being more susceptible than elastic arteries. The endothelial dysfunction as a result of GPR18 deletion was confirmed in femoral artery segments studied ex vivo in the presence of indomethacin (Figure 1C) The lack of changes in sensitivity to NO donors, both in vivo and ex vivo (insets in Figure 1A–C), suggests that the dysfunction reflects impaired endothelial NO production. Previous studies have established NO‐mediated vasorelaxation by GPR18 agonists [13, 14], and the present study extends the GPR18‐NO link to an observed significant reduction in endothelial NO synthase (eNOS) protein levels in femoral arteries after GPR18 deletion (Figure 1D).

FIGURE 1.

FIGURE 1

Upper panels show In vivo MRI examinations of endothelial function in the femoral artery (A) and thoracic aorta (B) in response to acetylcholine (ACh, 16.6 mg/kg i.p.) administered to female wildtype (WT, open symbols, n = 6 for the femoral artery and n = 4 for the thoracic aorta) and GPR18 knockout (KO, green symbols, n = 5 for the femoral artery and n = 44 for the thoracic aorta) mice. The unaltered endothelium‐independent responses to infusion of the NO‐donor to sodium nitroprusside (SNP, 1 mg/kg i.v.; WT: N = 5 for the femoral artery and n = 3 for the thoracic aorta; KO: N = 5 for the femoral artery and n = 4 for the thoracic aorta) are shown as insets. Results are shown as changes in vessel volume. The horizontal line represents the mean. p‐value from Student's t‐test vs. WT. (C) Ex vivo analysis of endothelium‐dependent relaxations in response to ACh administered to 10 μM PE‐precontracted arterial rings of the femoral artery derived from female mice (WT, n = 7; KO, n = 9) in the presence of 10 μM indomethacin. Inset shows endothelial‐independent relaxations in response to DEANO measured in 10 μM PE‐precontracted arterial rings of the femoral artery (WT, n = 8; KO, n = 8), in the presence of 10 μM indomethacin and 300 μM L‐NAME, to inhibit any possible confounding effects of endogenous NOS or COX activity, respectively. The overall P of significant two‐way ANOVA comparison of KO vs. WT is indicated in each concentration‐response graph. *p < 0.05 (Holm‐Sidak post hoc test vs. WT). (D) Representative images and analysis of immunofluorescent staining for endothelial nitric oxide synthase (eNOS) in femoral arteries derived from female GPR18 KO (green circles, n = 3) compared with female WT mice (open circles, n = 4). The horizontal line represents the mean; P‐value from Student's t‐test vs. WT. The micrographs show representative immunofluorescence stainings. Size bar represents 50 μm. (E) Concentration‐response relaxations to acetylcholine (ACh) in the absence (circles; WT, n = 7; KO, n = 10) and presence (squares; WT, n = 7; KO, n = 9) of 10 μM indomethacin in 10 μM PE‐precontracted isolated femoral arteries derived from female WT (left panel with open symbols) and GPR18 KO (left panel with green symbols). The overall p of two‐way ANOVA comparison of KO vs. WT is indicated in each concentration‐response graph. *p < 0.05 (Holm‐Sidak post hoc test vs. WT).

The activity of eNOS is known to vary across vascular beds [15] and is influenced by both vessel structure and local mechanical stimuli such as cyclic stretch and shear stress [16], which are absent in ex vivo assays. This greater NO dependence of in vivo vasodilation may explain the more pronounced effects observed in MRI studies. Notably, the ex vivo ACh‐induced relaxations were improved in the absence of indomethacin, with a larger effect in femoral arteries derived from GPR18 KO compared with WT mice (Figure 1E), suggesting partial compensation of endothelial dysfunction by prostanoid‐mediated vasorelaxation in the setting of reduced NO bioavailability by GPR18 deletion though further mechanistic studies are needed to confirm this contribution.

By showing that endogenous GPR18 expression is required for muscular artery endothelial health under physiological conditions, our findings extend previous work in a murine hypertension model, where treatment with the pro‐resolving GPR18 agonist RvD2 improved endothelial function in resistance but not elastic arteries [8]. In addition, GPR18‐dependent femoral artery endothelial modulation may also be involved in the established slower perfusion recovery after hind limb ischemia in GPR18 KO compared with WT mice [17]. These results have potential translational relevance, as they identify GPR18 expression as a determinant of vascular bed–specific endothelial responses and highlight a possible therapeutic opportunity to stimulate GPR18 signaling for preserving endothelial function under both acute and chronic pathophysiological processes, as well as in healthy aging.

Since endothelial dysfunction is a hallmark of aging and hypertension [18], we next explored the implications of GPR18 deletion on age‐dependent changes in blood pressure by determining systemic hemodynamic consequences of GPR18 deletion with in vivo continuous telemetry blood pressure measurement. In young mice, GPR18 deletion did not alter mean arterial blood pressure (MAP) during either the day or night in either sex‐disaggregated (Figure 2A,B) or sex aggregated analysis (Figure 2C). In contrast, 21‐month‐old GPR18 KO mice displayed significantly higher daytime MAP compared with age‐matched controls, with only modest changes during the night (Figure 2D). This phenotype resembles human night‐time hypertension in reverse—i.e., elevated resting‐phase pressure—which has been linked to endothelial dysfunction in aging. The circadian nature of this hypertensive pattern points to an age‐dependent interaction between GPR18 deficiency, vascular tone regulation, and circadian blood pressure homeostasis.

FIGURE 2.

FIGURE 2

Telemetry mean arterial blood pressures (MAP) in young (A–C) and old (D) WT (open symbols) and GPR18 KO (green symbols) mice. Each datapoint represents the MAP recorded during 1 h for all mice of each group during 3 days and nights. (A, B): The comparison between males (WT, n = 3; KO, n = 3) and females (WT, n = 4; KO, n = 3) in sex‐disaggregated analysis did not reveal any significant sex differences in either WT or GPR18 KO young mice. (C): In the sex aggregated analysis, with young KO (n = 7; n = 3 males [4.64 ± 0.51 months] and n = 4 females [4.13 ± 0.19 months]) did not exhibit any significant differences compared with young WT (n = 7; n = 3 males [4.49 ± 0.45 months] and n = 4 females [4.13 ± 0.08 months]) during either day or night. (D): Old KO (n = 4 [3 females and 1 male; 20.7 ± 0.63 months]) exhibited a significantly increased MAP during daytime and a moderate increase during active night‐time compared with old WT mice (n = 4 [2 females and 2 males; 21.3 ± 0.48 months]).

While the atheroprotective effects of GPR18 are transduced in myeloid cells, this study provides the first evidence that GPR18 is critical for maintaining endothelial function in muscular, but not elastic, arteries, and for preventing the development of an age‐associated, circadian‐pattern hypertensive phenotype. Since limitations of this study include the majority of experiments being conducted in female mice and the lack of sex‐disaggregated analysis in aged mice, it is acknowledged that further studies are needed to explore potential sex‐specific effects. Although the endogenous signaling mechanisms remain to be fully elucidated, given that GPR18 can transduce effects of both SPM and cannabinoid agonists, the results of the present study underscore the importance of GPR18 signaling in maintaining vascular health and preventing the transition from physiological to pathological aging.

Author Contributions

M.B. and S.C. designed the research study. S.M., B.S., A.B., M.‐D.L.‐R., J.L., N.M. performed the research. S.M., B.S., A.B., F.T.Y., N.M., analyzed the data. F.T.Y., S.C., N.M., M.B. provided supervision of the study. All authors contributed to writing and editorial changes in the manuscript. All authors read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Supporting information

Data S1: fsb271245‐sup‐0001‐supinfo.pdf.

FSB2-39-e71245-s001.pdf (101.7KB, pdf)

Acknowledgments

The authors wish to thank Cindy Lerognon, Zohra Younsi, Zeinep Berkimbayeva, Brygida Marczyk, Maud Collin and the ACBS animal facility for excellent technical support. Supported by CARE‐IN‐HEALTH funded by the European Union within HORIZON EUROPE Health Framework Program under grant agreement 101 095 413. Views and opinions expressed are however those of the authors and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. M.B. was supported by the Swedish Research Council (Vetenskapsrådet, grant number 2023‐02652), Heart‐Lung Foundation (Hjärt‐Lungfonden, grant number 20240697), and Region Stockholm (Stockholms läns landsting, grant number RS2023‐0859).

de Moudt S., Sitek B., Bar A., et al., “Vascular Bed‐Specific Endothelial Dysfunction and Age‐Dependent Circadian Hypertension in Mice Lacking the Resolvin D2 Receptor GPR18 ,” The FASEB Journal 39, no. 23 (2025): e71245, 10.1096/fj.202503386R.

Funding: This work was supported by CARE‐IN‐HEALTH funded by the European Union within HORIZON EUROPE Health Framework Program under grant agreement 101095413. Views and opinions expressed are however those of the authors and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. M.B. was supported by the Swedish Research Council (Vetenskapsrådet, grant number 2023‐02652), Heart‐Lung Foundation (Hjärt‐Lungfonden, grant number 20240697), and Region Stockholm (Stockholms läns landsting, grant number RS2023‐0859).

Data Availability Statement

The data that support the findings of this study are available in the Materials and Methods, Results, and/or Data S1 of this article.

References

  • 1. Bäck M., Yurdagul A., Tabas I., Öörni K., and Kovanen P. T., “Inflammation and Its Resolution in Atherosclerosis: Mediators and Therapeutic Opportunities,” Nature Reviews. Cardiology 16, no. 7 (2019): 389–406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Fredman G. and Serhan C. N., “Specialized Pro‐Resolving Mediators in Vascular Inflammation and Atherosclerotic Cardiovascular Disease,” Nature Reviews. Cardiology 21, no. 11 (2024): 808–823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Pirault J. and Bäck M., “Lipoxin and Resolvin Receptors Transducing the Resolution of Inflammation in Cardiovascular Disease,” Frontiers in Pharmacology 9 (2018): 1273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Serhan C. N., “Pro‐Resolving Lipid Mediators Are Leads for Resolution Physiology,” Nature 510, no. 7503 (2014): 92–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Nshimiyimana R., Simard M., Teder T., et al., “Biosynthesis of Resolvin D1, Resolvin D2, and RCTR1 From 7,8(S,S)‐Epoxytetraene in Human Neutrophils and Macrophages,” Proceedings of the National Academy of Sciences of the United States of America 121, no. 37 (2024): e2405821121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Bardin M., Pawelzik S. C., Lagrange J., et al., “The Resolvin D2 ‐ GPR18 Axis Is Expressed in Human Coronary Atherosclerosis and Transduces Atheroprotection in Apolipoprotein E Deficient Mice,” Biochemical Pharmacology 201 (2022): 115075. [DOI] [PubMed] [Google Scholar]
  • 7. Viola J. R., Lemnitzer P., Jansen Y., et al., “Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice,” Circulation Research 119, no. 9 (2016): 1030–1038. [DOI] [PubMed] [Google Scholar]
  • 8. Del Diaz Campo L. S., del Díaz Campo L. S., García‐Redondo A. B., et al., “Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II‐Induced Hypertension,” Hypertension 80, no. 1 (2023): 84–96. [DOI] [PubMed] [Google Scholar]
  • 9. Rodrigues‐Diez R., Ballesteros‐Martinez C., Moreno‐Carriles R. M., et al., “Resolvin D2 Prevents Vascular Remodeling, Hypercontractility and Endothelial Dysfunction in Obese Hypertensive Mice Through Modulation of Vascular and Proinflammatory Factors,” Biomedicine & Pharmacotherapy 174 (2024): 116564. [DOI] [PubMed] [Google Scholar]
  • 10. Lipscomb M., Walis S., Marinello M., et al., “Resolvin D2 Limits Atherosclerosis Progression via Myeloid Cell‐GPR18,” FASEB Journal 38, no. 6 (2024): e23555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Bellotti P., Ladd Z., Leroy V., et al., “Resolvin D2/GPR18 Signaling Enhances Monocytic Myeloid‐Derived Suppressor Cell Function to Mitigate Abdominal Aortic Aneurysm Formation,” FASEB Journal 38, no. 18 (2024): e70067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Spite M., Norling L. V., Summers L., et al., “Resolvin D2 Is a Potent Regulator of Leukocytes and Controls Microbial Sepsis,” Nature 461, no. 7268 (2009): 1287–1291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Kotanska M., Kubacka M., Bednarski M., et al., “The GPR18 Agonist PSB‐KD‐107 Exerts Endothelium‐Dependent Vasorelaxant Effects,” Pharmaceuticals (Basel) 14, no. 8 (2021): 799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Kozlowska H., Malinowska B., Baranowska‐Kuczko M., et al., “GPR18‐Mediated Relaxation of Human Isolated Pulmonary Arteries,” International Journal of Molecular Sciences 23, no. 3 (2022): 1427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Heaps C. L., Bray J. F., McIntosh A. L., and Schroeder F., “Endothelial Nitric Oxide Synthase Protein Distribution and Nitric Oxide Production in Endothelial Cells Along the Coronary Vascular Tree,” Microvascular Research 122 (2019): 34–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Leloup A. J., “Elastic and Muscular Arteries Differ in Structure, Basal NO Production and Voltage‐Gated ca(2+)‐Channels,” Frontiers in Physiology 6 (2015): 375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Zhang M. J., Sansbury B. E., Hellmann J., et al., “Resolvin D2 Enhances Postischemic Revascularization While Resolving Inflammation,” Circulation 134, no. 9 (2016): 666–680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Alexander Y., Osto E., Schmidt‐Trucksäss A., et al., “Endothelial Function in Cardiovascular Medicine: A Consensus Paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis,” Cardiovascular Research 117, no. 1 (2021): 29–42. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data S1: fsb271245‐sup‐0001‐supinfo.pdf.

FSB2-39-e71245-s001.pdf (101.7KB, pdf)

Data Availability Statement

The data that support the findings of this study are available in the Materials and Methods, Results, and/or Data S1 of this article.


Articles from The FASEB Journal are provided here courtesy of Wiley

RESOURCES